Tumor Mutational Burden - Molecular HealthMolecular Health

Have a question?

Phone +1-978-491-8393

Whitepaper: Tumor Mutational Burden

The Tumor Mutational Burden (TMB) is a genomic biomarker. Recent studies indicate that TMB
predicts clinical response to Immune Checkpoint Inhibitors (ICI) such as Keytruda (pembrolizumab)
even across all solid cancer types. However, other recent studies could not show a significant
association with efficacy of pembrolizumab plus carboplatin and pemetrexed or carboplatin and
pemetrexed alone as first-line therapy for metastatic nonsquamous NSCLC.

To download this whitepaper please submit the form below:

I agree that my name, email address, and any other information I provide, can be transferred to Molecular Health GmbH and processed there for the purpose of answering my request. I have read the privacy policy and hereby agree that my personal data may be processed as described. I can revoke this agreement at any time.